Retraction Note: Biotechnologische Konzepte zur Behandlung von Rückenschmerzen. Erste Erfahrungen mit Alternativen zu Glukokortikoiden

[1]  Ronald L. White,et al.  Epidural steroids, etanercept, or saline in subacute sciatica: a multicenter, randomized trial. , 2012 .

[2]  S. Kishida,et al.  Epidural Administration of Spinal Nerves With the Tumor Necrosis Factor-Alpha Inhibitor, Etanercept, Compared With Dexamethasone for Treatment of Sciatica in Patients With Lumbar Spinal Stenosis: A Prospective Randomized Study , 2012, Spine.

[3]  S. Viatte,et al.  Adalimumab in acute sciatica reduces the long-term need for surgery: a 3-year follow-up of a randomised double-blind placebo-controlled trial , 2011, Annals of the rheumatic diseases.

[4]  C. Kawcak,et al.  Autologous Conditioned Serum in the Treatment of Orthopedic Diseases , 2012, BioDrugs.

[5]  C. Birbara,et al.  Efficacy and safety of tanezumab in the treatment of chronic low back pain , 2011, PAIN®.

[6]  P. Wehling,et al.  464 INTRADISCAL INJECTIONS OF ORTHOKINE-DERIVED AUTOLOGOUS CONDITIONED SERUM (ACS) FOR LUMBAR DISC DEGENERATION , 2011 .

[7]  L. Setton,et al.  Attenuation of Inflammatory Events in Human Intervertebral Disc Cells With a Tumor Necrosis Factor Antagonist , 2011, Spine.

[8]  B. Winkelstein,et al.  Inflammatory Cytokine and Chemokine Expression Is Differentially Modulated Acutely in the Dorsal Root Ganglion in Response to Different Nerve Root Compressions , 2011, Spine.

[9]  N. Daraboš,et al.  Intraarticular application of autologous conditioned serum (ACS) reduces bone tunnel widening after ACL reconstructive surgery in a randomized controlled trial , 2011, Knee Surgery, Sports Traumatology, Arthroscopy.

[10]  S. Viatte,et al.  Adalimumab in severe and acute sciatica: a multicenter, randomized, double-blind, placebo-controlled trial. , 2010, Arthritis and rheumatism.

[11]  M. Schiltenwolf,et al.  Zur Rolle der Zytokine bei Patienten mit Rückenschmerz und Fibromyalgie , 2010, Der Schmerz.

[12]  S. Longworth,et al.  Tumor Necrosis α-blocking Agent (Etanercept): A Triple Blind Randomized Controlled Trial of its Use in Treatment of Sciatica , 2010, Journal of spinal disorders & techniques.

[13]  V. Mehta.  Platelet-rich plasma: a review of the science and possible clinical applications. , 2010, Orthopedics.

[14]  Steven P. Cohen,et al.  Randomized, Double-blind, Placebo-controlled, Dose-response, and Preclinical Safety Study of Transforaminal Epidural Etanercept for the Treatment of Sciatica , 2009, Anesthesiology.

[15]  X. Pang,et al.  Expression and Role of Connective Tissue Growth Factor in Painful Disc Fibrosis and Degeneration , 2009, Spine.

[16]  R. Krauspe,et al.  Autologous conditioned serum (Orthokine) is an effective treatment for knee osteoarthritis. , 2009, Osteoarthritis and cartilage.

[17]  S. Ohtori,et al.  Direct Application of the TNF-Alpha Inhibitor, Etanercept, Does Not Affect CGRP Expression and Phenotypic Change of DRG Neurons Following Application of Nucleus Pulposus Onto Injured Sciatic Nerves in Rats , 2008, Spine.

[18]  W. Willems,et al.  Autologous interleukin-1 receptor antagonist improves function and symptoms in osteoarthritis when compared to placebo in a prospective randomized controlled trial. , 2008, Osteoarthritis and cartilage.

[19]  E. Burright,et al.  Effect of Etanercept, a Tumor Necrosis Factor-Alpha Inhibitor, on Neuropathic Pain in the Rat Chronic Constriction Injury Model , 2008, Spine.

[20]  R. Willburger,et al.  Efficacy of Epidural Perineural Injections With Autologous Conditioned Serum for Lumbar Radicular Compression: An Investigator-Initiated, Prospective, Double-Blind, Reference-Controlled Study , 2007, Spine.

[21]  Steven P. Cohen,et al.  A Double-blind, Placebo-controlled, Dose–Response Pilot Study Evaluating Intradiscal Etanercept in Patients with Chronic Discogenic Low Back Pain or Lumbosacral Radiculopathy , 2007, Anesthesiology.

[22]  H. An,et al.  Proinflammatory Cytokines Stimulate the Expression of Nerve Growth Factor by Human Intervertebral Disc Cells , 2007, Spine.

[23]  J. Niinimäki,et al.  The Treatment of Disc Herniation-Induced Sciatica With Infliximab: One-Year Follow-up Results of FIRST II, a Randomized Controlled Trial , 2006, Spine.

[24]  J. Niinimäki,et al.  The Treatment of Disc Herniation-Induced Sciatica With Infliximab: Results of a Randomized, Controlled, 3-Month Follow-up Study , 2005, Spine.

[25]  C. Botsios.  Safety of tumour necrosis factor and interleukin-1 blocking agents in rheumatic diseases. , 2005, Autoimmunity reviews.

[26]  J. Niinimäki,et al.  Efficacy of Infliximab for Disc Herniation-Induced Sciatica: One-Year Follow-up , 2004, Spine.

[27]  E. Tobinick,et al.  Efficacy of etanercept delivered by perispinal administration for chronic back and/or neck disc-related pain: a study of clinical observations in 143 patients , 2004, Current medical research and opinion.

[28]  S. Genevay,et al.  Efficacy of etanercept in the treatment of acute, severe sciatica: a pilot study , 2004, Annals of the rheumatic diseases.

[29]  P. Wehling,et al.  The production of anti-inflammatory cytokines in whole blood by physico-chemical induction , 2003, Inflammation Research.

[30]  J. Niinimäki,et al.  Tumor Necrosis Factor-&agr; Monoclonal Antibody, Infliximab, Used to Manage Severe Sciatica , 2003, Spine.

[31]  K. Olmarker,et al.  Tumor Necrosis Factor α and Nucleus‐Pulposus‐Induced Nerve Root Injury , 1998 .

[32]  K. Heininger,,et al.  Neurophysiologic Changes in Lumbar Nerve Root Inflammation in the Rat After Treatment With Cytokine Inhibitors: Evidence for a Role of Interleukin‐1 , 1996, Spine.

[33]  W. Arend.  Interleukin-1 receptor antagonist. , 1993, Advances in immunology.